Genocea Biosciences (NASDAQ:GNCA) presented positive Phase 1/2a data regarding its neoantigen vaccine candidate, GEN-009, at the American Society of Clinical Oncology annual meeting.
GEN-009 is a personalized cancer vaccine that uses Genocea’s ATLAS platform to identify the neoantigens most likely to have an immunostimulatory effect, based on the mutations in a patient’s tumor.
Genocea reported that in the five patients with available immune response results, GEN-009 elicited T cell responses to 91% of the vaccine neoantigens administered.
“These data clearly differentiate ATLAS, our neoantigen discovery platform, from first-generation, machine-based approaches,” Chip Clark, Genocea’s president and CEO, said in a statement.
“As we continue to say, “targets matter,” and these data highlight the necessity of selecting the right neoantigens to drive immune responses in cancer patients,” he added.
The ongoing Phase 1/2a study is being conducted across a variety of cancer types and is expected to generate nine evaluable patients. Genocea is also developing GEN-011, a neoantigen-specific adoptive T cell therapy, for which it intends to file an IND in the first half of 2020.
